Response letter to "Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers"

被引：0
|
作者：
Ichimura, Takenori [1 ,2 ]
机构：
[1] Univ Sch Pharm, Dept Hosp Pharmaceut, Tokyo, Japan
[2] Showa Univ, Dept Hosp Pharmaceut, Sch Pharm, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428555, Japan
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2023年 / 29卷 / 04期
关键词：
GEMCITABINE; CISPLATIN;
D O I：
10.1177/10781552231165235
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1025 / 1026
页数：2
相关论文
共 50 条
  • [21] Second-line chemotherapy in advanced biliary tract cancer: Who may benefit?
    Salati, Massimiliano
    Caputo, Francesco
    Marcheselli, Luigi
    Rimini, Margherita
    Spallanzani, Andrea
    Gelsomino, Fabio
    Andrikou, Kalliopi
    Zironi, Sandra
    Di Emidio, Katia
    Clo', Vera
    Luppi, Gabriele
    Cascinu, Stefano
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [22] Outcome of second-line chemotherapy for biliary tract cancer
    Bridgewater, John
    Palmer, Daniel
    Cunningham, David
    Iveson, Tim
    Gillmore, Roopinder
    Waters, Justin
    Harrison, Mark
    Wasan, Harpreet
    Corrie, Pippa
    Valle, Juan
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1511 - 1511
  • [23] Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
    Adhikaree, Jason
    Madhusudan, Srinivasan
    MEDICAL ONCOLOGY, 2014, 31 (07)
  • [24] Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
    Jason Adhikaree
    Srinivasan Madhusudan
    Medical Oncology, 2014, 31
  • [25] EFFICACY AND SAFETY OF S-1 AS SECOND-LINE CHEMOTHERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCER
    Kobayashi, S.
    Ueno, M.
    Ohkawa, S.
    Andou, T.
    Kameda, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 121 - 121
  • [26] Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
    Fiteni, Frederic
    Jary, Marine
    Monnien, Franck
    Nguyen, Thierry
    Beohou, Eric
    Demarchi, Martin
    Dobi, Erion
    Fein, Francine
    Cleau, Denis
    Fratte, Serge
    Nerich, Virginie
    Bonnetain, Franck
    Pivot, Xavier
    Borg, Christophe
    Kim, Stefano
    BMC GASTROENTEROLOGY, 2014, 14
  • [27] Combination therapy with capecitabine and cisplatin as second-line chemotherapy for advanced biliary tract cancer
    Jung, Jang Han
    Chung, Moon Jae
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    Park, Jeong Youp
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 210 - 210
  • [28] Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
    Frédéric Fiteni
    Marine Jary
    Franck Monnien
    Thierry Nguyen
    Eric Beohou
    Martin Demarchi
    Erion Dobi
    Francine Fein
    Denis Cleau
    Serge Fratté
    Virginie Nerich
    Franck Bonnetain
    Xavier Pivot
    Christophe Borg
    Stefano Kim
    BMC Gastroenterology, 14
  • [29] Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
    Fornaro, L.
    Cereda, S.
    Aprile, G.
    Di Girolamo, S.
    Santini, D.
    Silvestris, N.
    Lonardi, S.
    Leone, F.
    Milella, M.
    Vivaldi, C.
    Belli, C.
    Bergamo, F.
    Lutrino, S. E.
    Filippi, R.
    Russano, M.
    Vaccaro, V.
    Brunetti, A. E.
    Rotella, V.
    Falcone, A.
    Barbera, M. A.
    Corbelli, J.
    Fasola, G.
    Aglietta, M.
    Zagonel, V.
    Reni, M.
    Vasile, E.
    Brandi, G.
    BRITISH JOURNAL OF CANCER, 2014, 110 (09) : 2165 - 2169
  • [30] Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
    L Fornaro
    S Cereda
    G Aprile
    S Di Girolamo
    D Santini
    N Silvestris
    S Lonardi
    F Leone
    M Milella
    C Vivaldi
    C Belli
    F Bergamo
    S E Lutrino
    R Filippi
    M Russano
    V Vaccaro
    A E Brunetti
    V Rotella
    A Falcone
    M A Barbera
    J Corbelli
    G Fasola
    M Aglietta
    V Zagonel
    M Reni
    E Vasile
    G Brandi
    British Journal of Cancer, 2014, 110 : 2165 - 2169
12345